Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V2KR
|
|||
| Former ID |
DIB007182
|
|||
| Drug Name |
Yttrium (90Y) clivatuzumab tetraxetan
|
|||
| Synonyms |
PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [1], [2] | |
| Company |
Immunomedics; Garden State Cancer Center; Immunomedics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [3] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8087). | |||
| REF 2 | ClinicalTrials.gov (NCT01956812) Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Immunomedics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.